Mir 1205 mimic

Docetaxel (DOC) was purchased from MCE (Beijing, China). miR-1205 mimic was purchased from Ribobio (Guangzhou, China). Chemicals were purchased from Sigma-Aldrich (St Louis, USA). Antibodies were purchased from Santa Cruz Biotechnology (Dallas, USA) and Abcam (Cambridge, USA). The antibodies used in this study were as follows: DNAJB1 (sc-398766, 1:1000 for western blotting, 1:100 for Co-IP; Santa Cruz), p53 (ab32389, 1:1000 for western blotting, 1:200 for Co-IP; Abcam), p63 (1:1000 for western blotting, 1:200 for Co-IP) (ab124762; Abcam), ATM (ab199726, 1:1000; Abcam), Bax (ab32503, 1:1000; Abcam), GAPDH (sc-365062, 1:500; Santa Cruz). Other chemicals and reagents were purchased from Beyotime (Nantong, China) and Sangon (Shanghai, China).

Plasmid-mediated circRNA overexpression and knockdown vector were obtained from Oebiotech (Shanghai, China), siRNAs targeting circRNA were obtained from GenePharma (Suzhou, China), miR-1205 mimic was ordered from RiboBio (Guangzhou, China), and the lentiviral expression vector of miR-1205 inhibitor and control plasmid were ordered from GeneCopoeia (Rockville, MD, USA). Cells were seeded in 6-well plates 24 h prior to miR-1205 mimic or inhibitor transfection with 50%–60% confluence and then were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. For stable transfections, we first established circRNA-0003506 and negative vector stable expressing cells using Puromycin selection methods.